Guanylyl cyclase Inhibitors
2 drugsAbout Guanylyl cyclase
Guanylyl cyclase (GC) enzymes are receptors that catalyze cyclic GMP (cGMP) production, a second messenger involved in various physiological processes like vasodilation and smooth muscle relaxation.
Guanylyl cyclase's role in regulating vasodilation makes it a valuable cardiovascular drug target, though no direct genetic evidence currently links it to specific diseases.
Two approved drugs target guanylyl cyclase: BIDIL and ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE, both small molecules for cardiovascular applications.
Top Guanylyl cyclase Drugs
The competitive landscape includes two companies with approved drugs: AZURITY and INGENUS PHARMS LLC.
Low market concentration suggests opportunities for new entrants, but also potential pricing pressure.
Guanylyl cyclase Drug Modality Landscape
Modalities
Routes of Administration
Guanylyl cyclase is amenable to small molecule drugs, with oral options available for convenient dosing.
Explore alternative modalities like biologics to differentiate from existing small molecule drugs.
Guanylyl cyclase Clinical Trials 18 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Guanylyl cyclase. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 3 | 3 | 0 | 0 | 100% |
| Phase 2 | 5 | 5 | 0 | 0 | 100% |
| Phase 3 | 3 | 3 | 0 | 0 | 100% |
| Phase 4 | 7 | 5 | 0 | 2 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Guanylyl cyclase Drug Approval Timeline (2005 - 2022)
The first drug was approved in 2005 (BIDIL), with the most recent in 2022.
The approval timeline indicates continued interest, but also suggests potential market saturation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 17 (1 company)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Guanylyl cyclase. A trial counts if an approved drug acting on Guanylyl cyclase is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.